MAPK signaling is overactive in the majority of CMs, driven by activating mutations in BRAF (~50%) or NRAS (~25%), or loss of function mutations in NF1 (~15%) (Genomic Classification of Cutaneous Melanoma, 2015). The gene discussed is BRAF; the disease is cutaneous melanoma.